Participants described how comorbidities, payer formularies, and patient preference shape biologic choice in asthma and COPD.
News|Videos|December 31, 2024
This Year in Pulmonology: The 2024 Lungcast Recap
Author(s)Tim Smith
Lungcast reflects on this year in pulmonology, looking back at such topics ranging from the American Lung Association ‘State of the Air’ report to artificial intelligence in lung imaging.
Advertisement
Advertisement
If one were to look back on the year of 2024 in pulmonology, the most notable developments would be almost too numerous to mention.
Related to this article
Repeated oral steroid bursts are the main trigger for starting a biologic, while therapy for non-type 2 inflammation COPD remains an unmet need.
Clinicians at CHEST 2026 will see late-breaking COPD, asthma, pulmonary hypertension, and bronchoscopy data, plus exclusive expert interviews.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, recap the first-ever Breakthrough T1D Clinical and Research Congress.
Topline phase 3 ALOFT-IPF data show admilparant 60 mg improved 52-week FVC vs placebo in IPF, while the 120 mg dose missed statistical significance.
Jasmohan Bajaj, MD, joins Nancy Reau, MD, and Kim Brown, MD, to review what is new in the ACG hepatic encephalopathy guideline.
Sarina Berger Elmariah, MD, PhD, MPH, discusses 3-year nemolizumab data in early responders and what IL-31 blockade means for itch and atopic dermatitis.
Alpha-gal syndrome is reaching new regions, but delayed reactions and GI-only symptoms can leave patients undiagnosed for months or years.
Advertisement
Advertisement